Study directory

Depression studies

Compare studies and check their requirements with the research team.

6115studies shown

Showing 1,657-1,668 of 6,115

CompletedEUCTR 2010-022257-41

A Multinational, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of Lu AA21004 in Patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Finland

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Finland, Germany, Latvia, ...
Sponsor: Takeda Global Research and Development Centre (Europe) Ltd.
Condition: Depression

View study

CompletedEUCTR 2011-002362-21

A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: United Kingdom, Belgium, Austria, ...
Sponsor: H. Lundbeck A/S
Condition: Depression

View study

TerminatedEUCTR 2012-004132-33

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features (Protocol No D1050304)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom

Why is this study shown?

This study is directly about Depression.

Depression, BipolarityDrug

Countries: United Kingdom
Sponsor: Sunovion Pharmaceuticals Inc.
Condition: Depression, Bipolarity

View study

CompletedEUCTR 2022-000461-41

A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France, Bulgaria, Czechia, ...
Sponsor: Janssen-Cilag International NV
Condition: Depression

View study

CompletedEUCTR 2011-001436-33

A randomized, double-blind, parallel-group study of the safety and efficacy of RO4917523 versus placebo, as adjunctive therapy in patients with major depressive disorder with inadequate response to...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Germany
Sponsor: F. Hoffmann-La Roche Ltd
Condition: Depression

View study

CompletedEUCTR 2008-008280-96

Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Germany
Sponsor: Department of Psychiatry and Psychotherapy, University of Mainz
Condition: Depression

View study

TerminatedEUCTR 2010-021044-17

The effect of agomelatine on CLOCK gene expression in patients with major depressive disorder and healthy controls: an exploratory study.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Austria
Sponsor: Medizinische Universität Wien
Condition: Depression

View study

Recruitment unclearEUCTR 2020-000341-14

A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: United Kingdom, Belgium, Bulgaria, ...
Sponsor: Janssen-Cilag International NV
Condition: Depression

View study

Recruitment unclearEUCTR 2010-020493-42

A Double-blind, Randomized, Placebo-controlled, Multicentre, Relapse-prevention Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Latvia, Poland, ...
Sponsor: H. Lundbeck A/S
Condition: Depression

View study

Recruitment unclearEUCTR 2019-001989-15

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Depression.

DepressionBiological

Countries: France, Czechia, Finland, ...
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Condition: Depression

View study

Not recruitingEUCTR 2010-018860-17

A Multicenter, 52-week, Open-label Study to Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients with Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Estonia, Finland, ...
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition: Depression

View study

Not recruitingEUCTR 2008-001580-11

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 3 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France, United Kingdom, Germany, ...
Sponsor: Takeda Global Research & Development Centre (Europe) Ltd.
Condition: Depression

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.